Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Chihiro Nakayama *Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.ORCID 0009-0000-7081-6222
Qi Fang *Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.ORCID 0009-0009-5296-1843
Yasukazu DaigakuCancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. yasukazu.daigaku@jfcr.or.jp.ORCID 0000-0002-8404-7492
Yuki AoiFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-0252-9536
Shoko ItoMedical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-2797-4177
Mami TakahashiCancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Reo ShimataniMedical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Tamiko MinamisawaCancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yagiz OzturkDivision of Molecular and Cell Biology, University of Leicester, Leicester, UK.ORCID 0009-0004-4351-7410
Hiroshi KimuraCell Biology Center, Institute of Integrated Research, Institute of Science Tokyo, Meguro, Tokyo, Japan.ORCID 0000-0003-0854-083X
Ali ShilatifardFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-7490-2854
Michael TellierDivision of Molecular and Cell Biology, University of Leicester, Leicester, UK. mt477@leicester.ac.uk.ORCID 0000-0002-4130-9050
Takayuki NojimaMedical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. nojima.takayuki.058@m.kyushu-u.ac.jp.ORCID 0000-0003-1236-4162
Funding
Mutations of Chromatin and its Modifying Machineries in MalignanciesR35CA197569 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Ali Shilatifard · 2015 to 2026
$10.7M
Astellas Foundation for Research on Metabolic Disorders naDaiichi Sankyo Foundation of Life Science naHHS | National Institutes of Health (NIH) R35CA197569MEXT Cooperative Research Project Program, Medical Research Center Initiative for High Depth Omics, and CURE JPMXP1323015486MEXT | Japan Society for the Promotion of Science (JSPS) JP25KJ1964MEXT | JST | Fusion Oriented REsearch for disruptive Science and Technology (FOREST) JPMJFR204XMEXT | JST | Fusion Oriented REsearch for disruptive Science and Technology (FOREST) JPMJFR2050MEXT | JST | Support for Pioneering Research Initiated by the Next Generation (SPRING) JPMJSP2136Ministry of Education, Culture, Sports, Science and Technology (MEXT) JP19K24692Ministry of Education, Culture, Sports, Science and Technology (MEXT) JP23H02463Ministry of Education, Culture, Sports, Science and Technology (MEXT) JP24K01957Princess Takamatsu Cancer Research Fund naRIKAKEN HD naRoyal Society (The Royal Society) ICA\R1\231018The Ichiro Kanehara Foundation for Promotion of Medical Sciences and Medical Care naThe Mitsubishi Foundation naThe Mochida Memorial Foundation for Medical and Pharmaceutical Research naThe Naito Foundation naThe NOVARTIS Foundation (Japan) for the Promotion of Science naThe Shinnihon Foundation of Advanced Medical Treatment Research naThe Sumitomo Foundation naThe Uehara Memorial Foundation naUKRI | Medical Research Council (MRC) MR/W007002/1University of Leicester F50 PhD studentship naYamada Science Foundation (YSF) na
6 · The paper itself
Abstract
Regulation of RNA polymerase II (Pol II) transcription is closely associated with cell proliferation. However, it remains unclear how the Pol II transcription program is rewired in cancer to promote uncontrolled growth. Here, we find that expression of NELFCD, a known negative transcription elongation factor, is upregulated in colorectal tumors. Auxin-dependent protein degradation of NELF-C in combination with nascent transcript sequencing demonstrates a direct role of NELF-C on Pol II transcription in this cancer. Strikingly, we demonstrate that the acute loss of NELF-C protein globally redistributes termination factors and perturbs Pol II transcription termination. These changes drive pervasive Pol II transcription into DNA replication zones, leading to transcription-replication conflict that may block the cell cycle in G1 or early S phase. Our findings reveal a previously unrecognized role of NELF in transcription termination and highlight NELF as a potential therapeutic target in colorectal cancer.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
NELF prevents transcriptional readthrough into DNA replication zones in cancer cells. · full record | Socratic